At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 331 enrolled
Drug / intervention
Lebrikizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adult and Adolescent Patients With Moderate-To-Severe Atopic Dermatitis That Are Not Adequately Controlled With Cyclosporine or For Whom Cyclosporine is Not Medically Advisable.
In Brief
A Phase 3 clinical trial evaluating Lebrikizumab and Lebrikizumab-matching Placebo for Dermatitis, Atopic and Eczema. Completed, enrolled 331 participants across 48 sites in 8 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy of lebrikizumab compared with placebo in participants not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic, Eczema
CountriesAustria, Belgium, France, Germany, Netherlands, Poland, Spain, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartDec 2021
Primary CompletionJan 2023
Study CompletionMay 2024
TodayJul 2026
First PostedDec 8, 2021
Enrollment StartDec 23, 2021
Primary CompletionJan 30, 2023
Study CompletionMay 7, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.6 years ago
Interventions
Lebrikizumabbiological
Lebrikizumab solution for injection administered subcutaneously.
Lebrikizumab-matching Placebodrug
Matching Placebo solution for injection administered subcutaneously.